1. |
ASXL |
Histone Modification |
Enhancer of trithorax and polycomb group (EAP) Additional sex combs like 1 |
Bohring-Opitz Syndrome, MDS and AML |
Mutation |
(Hoischen A, van Bon BW et al. 2011; Gelsi-Boyer V, Brecqueville M et al. 2012) |
2. |
BMI-1 |
Histone Modification |
PRC1 subunit |
Ovarian, mantle cell lymphomas and Merkel cell carcinomas |
Overexpression |
(Jiang L, Li J et al. 2009; Lukacs RU, Memarzadeh S et al. 2010) |
3. |
BRD4 |
Histone modification |
Bromodomain containing 4 |
Midline carcinoma, nuclear protein in testis, breast, colon, and AML |
Translocation (fusion protein), aberrant expression |
(Filippakopoulos P, Qi J et al. 2010; Zuber J, Shi J et al. 2011) |
4. |
CREBBP |
Histone Modification |
Histone acetyltransferase |
Colorectal, epithelial, gastric and ovarian, lung, esophageal cancer |
Mutation, overexpression |
(Miremadi A, Oestergaard MZ et al. 2007) |
5. |
EP300 |
Histone Modification |
Histone deacetyltransferase |
Colorectal, breast, pancreatic cancer |
Mutation |
(Miremadi A, Oestergaard MZ et al. 2007) |
6. |
EZH2 |
Histone Modification |
Histone methyltransferase H3K27 |
Colon, pancreas, liver, gastric, uterine tumors, breast, prostate, bladder, melanoma, lymphoma, myeloma, and Ewing’s sarcoma |
Mutation, aberrant expression |
(Chase A and Cross NC 2011; Tsang DP and Cheng AS 2011) |
7. |
G9a |
Histone Modification |
Histone methyltransferase H3K9 |
Cervical, uterine, HCC, ovarian, and breast cancer |
Aberrant expression |
(Varier RA and Timmers HT 2011) |
8. |
HDAC2 |
Histone Modification |
Histone deacetyltransferase |
Gastric, Colonic, endometrial cancer |
Mutation |
(Ropero S, Fraga MF et al. 2006) |
9. |
JARID1B/C |
Histone Modification |
Histone demethylase H3K4/H3K9 |
RCCC, testicular and breast, |
Overexpression |
(Rotili D 2011) |
10. |
LSD1 |
Histone Modification |
Histone demethylase H3K4/H3K9 |
Prostate |
Mutation |
(Rotili D 2011) |
11. |
MLL1/2/3 |
Histone modification |
Histone methyltransferase H3K4 |
Non-Hodgkin lymphoma, B cell lymphoma, Bladder TCC, ALL and AML, prostate (primary) |
Mutation, translocation, aberrant expression |
(Morin RD, Mendez-Lago M et al. 2011; Yaoting Gui, Guangwu Guo et al. 2011) |
12. |
PCAF |
Histone Modification |
Histone acetyltransferase |
Epithelial |
Mutation |
(Miremadi A, Oestergaard MZ et al. 2007) |
13. |
PRMT1/5 |
Histone Modification |
Protein arginine methyltransferase |
Breast/gastric |
Aberrant expression |
(Miremadi A, Oestergaard MZ et al. 2007) |
14. |
SIRT1, HDAC5/7A |
Histone modification |
Histone deacetyltransferase |
Colorectal, breast, prostate cancer |
Mutation, aberrant expression |
(Miremadi A, Oestergaard MZ et al. 2007) |
15. |
UTX (KDM6A) |
Histone Modification |
Histone demethylase H3K27 |
Breast, kidney, lung, pancreas, bladder, esophagus, colon, uterus, brain |
Mutation |
(Rotili D 2011) |
16. |
AID |
DNA methylation |
5’cytidine deaminase |
CML |
Aberrant expression |
(De Carvalho DD, You JS et al. 2010) |
17. |
DNMT1 |
DNA methylation |
DNA methyltransferase |
Pancreatic, gastric, breast, colorectal, non-small cell lung cancer |
Mutation, Overexpression |
(Kanai Y, Ushijima S et al. 2003; Wu SC and Zhang Y 2010) |
18. |
DNMT3A |
DNA methylation |
DNA methyltransferase |
MDS, AML |
Mutation |
(Ley TJ, Ding L et al. 2010; Yamashita Y, Yuan J et al. 2010) |
19. |
DNMT3B |
DNA methylation |
DNA methyltransferase |
ICF syndrome, SNPs in breast and lung adenoma |
Mutation |
(Wijmenga C, Hansen RS et al. 2000; Shen H, Wang L et al. 2002) |
20. |
IDH1/2 |
DNA methylation |
Isocitrate dehydrogenase |
Glioma, AML |
Mutation |
(Figueroa ME, Abdel-Wahab O et al. 2010; Lu C, Ward PS et al. 2012) |
21. |
MBD1/2 |
DNA methylation |
Methyl binding protein |
Breast and lung cancer |
Mutation |
(Sansom OJ, Maddison K et al. 2007) |
22. |
TET1 |
DNA methylation |
50methylcytosine hydroxylase |
AML |
Chromosome translocation |
(De Carvalho DD, You JS et al. 2010; Wu SC and Zhang Y 2010) |
23. |
TET2 |
DNA methylation |
50methylcytosine hydroxylase |
Myeloid malignancies (AML), MDS, gliomas |
Mutation/silenc ing |
(Tan AY and Manley JL 2009) |
24. |
ARID1A (BAF250A) |
Chromatin remodeling |
BAF subunit |
Carcinomas, endometrial carcinomas, ovarian clear cell carcinomas, 30% of endometrioid |
Mutation, genomic rearrangement, low expression |
(Jones S, Wang TL et al. 2010; Guan B, Mao TL et al. 2011) |
25. |
ARID2 (BAF200) |
Chromatin remodeling |
PBAF subunit |
Primary pancreatic adenocarcinomas |
Mutation |
(Li M, Zhao H et al. 2011) |
26. |
BRD7 |
Chromatin remodeling |
PBAF subunit |
Bladder TCC |
Mutation |
(Drost J, Mantovani F et al. 2010) |
27. |
BRG1(SMA CA4) |
Chromatin remodeling |
ATPase of BAF |
Lung, rhabdoid, medulloblastoma |
Mutation, low expression |
(Wilson BG and Roberts CW 2011) |
28. |
BRM (SMARCA2) |
Chromatin remodeling |
ATPase of BAF |
Prostate, basal cell carcinoma |
Mutation, low expression |
(Sun A, Tawfik O et al. 2007; de Zwaan SE and Haass NK 2010) |
29. |
CHD4/5 |
Chromatin remodeling |
ATPase of NURD |
Gastric and colorectal cancer, ovarian, prostate, neuroblastoma |
Mutation |
(Bagchi A, Papazoglu C et al. 2007; Kim MS, Chung NG et al. 2011; Wang J, Wu Z et al. 2012) |
30. |
CHD7 |
Chromatin remodeling |
ATP-dependent helicase |
Gastric and colorectal |
Mutation |
(Wessels K, Bohnhorst B et al. 2010) |
31. |
P400/Tip60 |
Chromatin remodeling |
ATPase of SWR1, acetylase of SWR1 |
lymphomas, colon, head-and-neck, breast |
Mutation, aberrant expression |
(Mattera L, Escaffit F et al. 2009) |
32. |
PBRM1 (BAF180) |
Chromatin remodeling |
PBAF subunit |
Breast tumor |
Mutation |
(Varela I, Tarpey P et al. 2011) |
33. |
SNF5 (SMARCB1, INI1) |
Chromatin remodeling |
Gastric and colorectal |
Kidney malignant rhabdoid tumors, atypical rhabdoid/teratoid tumors (extra-renal), epithelioid sarcomas, small cell hepatoblastomas, extraskeletal myxoid chondrosarcomas, and undifferentiated sarcomas |
Mutation, silencing, loss of expression |
(Wilson BG and Roberts CW 2011) |
34. |
SRCAP |
Chromatin remodeling |
ATPase of SWR1 |
Prostate |
Aberrant expression |
(Balakrishnan A, Bleeker FE et al. 2007) |